Intellia Therapeutics (NTLA) Operating Income (2016 - 2025)
Historic Operating Income for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to -$111.5 million.
- Intellia Therapeutics' Operating Income rose 2299.72% to -$111.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$478.7 million, marking a year-over-year increase of 1096.9%. This contributed to the annual value of -$534.3 million for FY2024, which is 368.18% down from last year.
- Intellia Therapeutics' Operating Income amounted to -$111.5 million in Q3 2025, which was up 2299.72% from -$110.0 million recorded in Q2 2025.
- Intellia Therapeutics' 5-year Operating Income high stood at -$46.4 million for Q1 2021, and its period low was -$144.8 million during Q3 2024.
- For the 5-year period, Intellia Therapeutics' Operating Income averaged around -$111.5 million, with its median value being -$112.0 million (2023).
- In the last 5 years, Intellia Therapeutics' Operating Income plummeted by 21070.76% in 2022 and then soared by 2299.72% in 2025.
- Intellia Therapeutics' Operating Income (Quarter) stood at -$80.4 million in 2021, then plummeted by 36.9% to -$110.1 million in 2022, then decreased by 27.07% to -$139.9 million in 2023, then rose by 2.46% to -$136.4 million in 2024, then increased by 18.3% to -$111.5 million in 2025.
- Its Operating Income was -$111.5 million in Q3 2025, compared to -$110.0 million in Q2 2025 and -$120.8 million in Q1 2025.